Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Income from Continuing Operations (2016 - 2026)

Pharma-Bio Serv's Income from Continuing Operations history spans 17 years, with the latest figure at 32860.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 284.96% year-over-year to 32860.0; the TTM value through Jan 2026 reached 85697.0, up 82.8%, while the annual FY2025 figure was 100463.0, 87.08% up from the prior year.
  • Income from Continuing Operations reached 32860.0 in Q1 2026 per PBSV's latest filing, up from 102.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 526242.0 in Q3 2023 to a low of 309194.0 in Q3 2024.
  • Average Income from Continuing Operations over 5 years is 86004.94, with a median of 32860.0 recorded in 2026.
  • Peak YoY movement for Income from Continuing Operations: tumbled 163.48% in 2024, then surged 284.96% in 2026.
  • A 5-year view of Income from Continuing Operations shows it stood at 173379.0 in 2022, then crashed by 127.19% to 47148.0 in 2023, then soared by 134.17% to 16111.0 in 2024, then plummeted by 100.63% to 102.0 in 2025, then soared by 32315.69% to 32860.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Income from Continuing Operations are 32860.0 (Q1 2026), 102.0 (Q4 2025), and 213808.0 (Q3 2025).